E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Management of Patients with Newly Diagnosed Chronic Myeloid Leukemia: Opportunities and Challenges
Elias Jabbour,Jorge E. Cortes,Susan O'Brien,Mary Beth Rios,Francis J. Giles,Hagop M. Kantarjian +5 more
TL;DR: The outlook today for patients with CML is much brighter than that of a few years ago and the understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance.
Journal ArticleDOI
Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution
Preetesh Jain,Hagop M. Kantarjian,Carlos Guillermo Romo,Alfonso Quintás-Cardama,Elias Jabbour,Marylou Cardenas-Turanzas,Sherry Pierce,Mary Joy Liboon,Evguenia Gachimova,Tapan M. Kadia,Gautam Borthakur,Farhad Ravandi,Susan O'Brien,Jorge E. Cortes +13 more
TL;DR: A single-institution experience of frequencies of non-hematological AE among pts on therapy with ponatinib among patients with refractory CML is reported, and four pts died, none related to p onatinib.
Journal ArticleDOI
Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma
Hussein A. Abbas,Patrick K. Reville,Alexis Geppner,Maro Ohanian,Koji Sasaki,Gautam Borthakur,Naval Daver,Courtney D. DiNardo,Carlos E. Bueso-Ramos,Michael Andreeff,Nicholas J. Short,Sherry Pierce,Elias Jabbour,Guillermo Garcia-Manero,Marina Konopleva,Farhad Ravandi,Hagop M. Kantarjian,Tapan M. Kadia +17 more
TL;DR: Inferior survival was noted in patients with baseline BM blasts >=5% and older age (>60 years) were not associated with OS, while the most common alterations seen in the MS tissue were: inv(16) in 4/22 (18%) and RAS pathway mutations in 4-18; 2 (9%) had complex cytogenetics, and 2 ( 9%) had NPM1 mutations.
Journal ArticleDOI
Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis
Tapan M. Kadia,Hongbing Ma,Ke Zeng,Mitsutaka Nishimoto,Mi-Ae Lyu,Meixian Huang,Musa Yilmaz,Courtney D. DiNardo,Ghayas C. Issa,Simrit Parmar,Swami P. Iyer,Parameswaran Hari,Naval Daver,Elias Jabbour,Gautam Borthakur,Srdan Verstovsek +15 more
TL;DR: It is hypothesized that adoptive therapy with CB Tregs can be utilized as treatment for the inflammatory bone marrow failure (BMF) disorders including aplastic anemia, hypoplastic myelodysplasia and primary myelofibrosis.
Journal ArticleDOI
Chronic Myeloid Leukemia— What Else is there Beyond Protein Kinase Inhibitors?
TL;DR: Omacetaxine, a protein translation inhibitor, has shown the potential to substantially reduce MRD in animal models and has demonstrated clinical activity in phase II clinical trials regardless of patients’ BCR-ABL T313I mutation status.